Core Viewpoint - Jiukang Bio has received a medical device registration certificate from the Beijing Drug Administration for its gastrin-17 assay kit, which is valid until September 11, 2030 [1] Group 1 - The product is named "Gastrin-17 Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay)" [1] - The kit is designed for the in vitro quantitative measurement of gastrin-17 (G-17) levels in human serum [1]

Core Viewpoint - Jiukang Bio (300406.SZ) has received a medical device registration certificate from the Beijing Drug Administration for its Gastrin-17 assay kit, which is expected to enhance the company's product range and core competitiveness, positively impacting future development, although it will not significantly affect recent production operations and performance [1] Company Summary - The newly acquired medical device registration certificate pertains to the Gastrin-17 assay kit, utilizing magnetic microparticle chemiluminescent immunoassay technology [1] - This development enriches the company's product categories, which is beneficial for strengthening its core competitiveness [1] - The impact on the company's recent production and operational performance is expected to be minimal [1]

Core Viewpoint - Jiukang Bio (300406.SZ) has recently received a Medical Device Registration Certificate from the Beijing Drug Administration for its product, the Gastrin-17 Assay Kit (Magnetic Microparticle Chemiluminescent Immunoassay), which enhances the company's product portfolio and core competitiveness, positively impacting future development, although it will not have a significant effect on recent production operations and performance [1] Company Summary - The acquisition of the Medical Device Registration Certificate enriches the company's product categories [1] - The new product is expected to strengthen the company's core competitiveness [1] - The impact on recent production and performance is not expected to be significant [1]